EGFR Inhibitor Market Expected to Gain Momentum Through 2034, According to DelveInsight | Merus, Cullinan Oncology, Taiho Pharma, Suzhou Puhe Pharma, TWi Biotech

The Key EGFR Inhibitor Companies in the market include - Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others.

DelveInsight's "EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the EGFR Inhibitor, historical and forecasted epidemiology as well as the EGFR Inhibitor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the EGFR Inhibitor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR Inhibitor Market Forecast [https://www.delveinsight.com/sample-request/egfr-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the EGFR Inhibitor Market Report:

*
The EGFR Inhibitor market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In June 2025, Dizal has finished enrolling participants for the randomized Phase III WU-KONG28 trial evaluating oral sunvozertinib in non-small cell lung cancer (NSCLC) patients. This multinational study aims to compare the safety and efficacy of the therapy against platinum-based doublet chemotherapies as a first-line treatment for NSCLC with EGFR exon 20 insertion mutations (exon20ins). WU-KONG28 is being conducted across 16 countries and regions, spanning Asia, North America, Europe, and South America.

*
In April 2025, Following its first-in-human clinical trial presentation of SYS6010 at AACR, CSPC Pharmaceuticals is advancing this anti-EGFR ADC into its initial phase 3 trial. This development is significant for ALX Oncology, which recently launched its EGFR ADC ALX2004, and for Lepu Biopharma, whose pivotal phase 2 study of the similarly targeted MRG003 has reportedly been chosen for an ASCO late-breaker presentation.

*
According to the SEER database, approximately 64,050 new cases of pancreatic cancer are expected in 2023. Additionally, the annual incidence rate of pancreatic cancer is 13.3 per 100,000 men and women.

*
According to a secondary analysis, EGFR alterations occur in 3.22% of colorectal carcinoma patients, with EGFR mutations found in 2.33% of all colorectal carcinoma cases.

*
Zubair et al. (2023) report that around 70% of patients with a sensitizing mutation initially respond to EGFR inhibitor therapy, but most develop resistance to these drugs after an average of 10-11 months.

*
Key EGFR Inhibitor Companies: Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others

*
Key EGFR Inhibitor Therapies: Petosemtamab (MCLA-158), Zipalertinib, YK-029A, AC-701, and others

*
The EGFR Inhibitor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR Inhibitor pipeline products will significantly revolutionize the EGFR Inhibitor market dynamics.

EGFR Inhibitor Overview

EGFR inhibitors are a class of medications used to treat certain types of cancer. EGFR stands for Epidermal Growth Factor Receptor, which is a protein on the surface of cells. This protein is involved in the growth and division of cells. In some cancers, EGFR is overactive or mutated, leading to uncontrolled cell growth.

Get a Free sample for the EGFR Inhibitor Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/egfr-market-forecast [https://www.delveinsight.com/report-store/egfr-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

EGFR Inhibitor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

EGFR Inhibitor Epidemiology Segmentation:

The EGFR Inhibitor market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of EGFR Inhibitor

*
Prevalent Cases of EGFR Inhibitor by severity

*
Gender-specific Prevalence of EGFR Inhibitor

*
Diagnosed Cases of Episodic and Chronic EGFR Inhibitor

Download the report to understand which factors are driving EGFR Inhibitor epidemiology trends @ EGFR Inhibitor Epidemiology Forecast [https://www.delveinsight.com/sample-request/egfr-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

EGFR Inhibitor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitor market or expected to get launched during the study period. The analysis covers EGFR Inhibitor market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the EGFR Inhibitor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

EGFR Inhibitor Therapies and Key Companies

*
Petosemtamab (MCLA-158): Merus

*
MCLA-129: Merus

*
Zipalertinib: Cullinan Oncology/Taiho Pharma

*
YK-029A: Suzhou Puhe Pharmaceutical

*
AC-701: TWi Biotechnology

Discover more about therapies set to grab major EGFR Inhibitor market share @ EGFR Inhibitor Treatment Landscape [https://www.delveinsight.com/sample-request/egfr-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

EGFR Inhibitor Market Strengths

*
MCLA-129 targets both EGFR and c-MET on cancer cells and offers significant potential opportunity in lung cancer.

*
First- to third-generation EGFR inhibitors have shown considerable efficacy and have significantly improved disease prognosis.

EGFR Inhibitor Market Opportunities

*
The challenge of overcoming intrinsic and acquired resistance in primary and recurrent cancer mediated by EGFR mutations is thus driving the search for alternative strategies in the design of new therapeutic agents.

*
Targeted protein degradation technology provides a new research direction for overcoming resistance to third-generation EGFR inhibitors.

Scope of the EGFR Inhibitor Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key EGFR Inhibitor Companies: Merus, Cullinan Oncology/Taiho Pharma, Suzhou Puhe Pharmaceutical, TWi Biotechnology, and others

*
Key EGFR Inhibitor Therapies: Petosemtamab (MCLA-158), Zipalertinib, YK-029A, AC-701, and others

*
EGFR Inhibitor Therapeutic Assessment: EGFR Inhibitor current marketed and EGFR Inhibitor emerging therapies

*
EGFR Inhibitor Market Dynamics: EGFR Inhibitor market drivers and EGFR Inhibitor market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
EGFR Inhibitor Unmet Needs, KOL's views, Analyst's views, EGFR Inhibitor Market Access and Reimbursement

To know more about EGFR Inhibitor companies working in the treatment market, visit @ EGFR Inhibitor Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/egfr-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. EGFR Inhibitor Market Report Introduction

2. Executive Summary for EGFR Inhibitor

3. SWOT analysis of EGFR Inhibitor

4. EGFR Inhibitor Patient Share (%) Overview at a Glance

5. EGFR Inhibitor Market Overview at a Glance

6. EGFR Inhibitor Disease Background and Overview

7. EGFR Inhibitor Epidemiology and Patient Population

8. Country-Specific Patient Population of EGFR Inhibitor

9. EGFR Inhibitor Current Treatment and Medical Practices

10. EGFR Inhibitor Unmet Needs

11. EGFR Inhibitor Emerging Therapies

12. EGFR Inhibitor Market Outlook

13. Country-Wise EGFR Inhibitor Market Analysis (2020-2034)

14. EGFR Inhibitor Market Access and Reimbursement of Therapies

15. EGFR Inhibitor Market Drivers

16. EGFR Inhibitor Market Barriers

17. EGFR Inhibitor Appendix

18. EGFR Inhibitor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=egfr-inhibitor-market-expected-to-gain-momentum-through-2034-according-to-delveinsight-merus-cullinan-oncology-taiho-pharma-suzhou-puhe-pharma-twi-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.